TBCRC 042 UAB 1905: A Randomized, Phase II, Window-of-Opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions

Grant

Date/time Interval

  • October 19, 2019 - October 18, 2024
  • Total Award Amount

  • 110432.00
  • Direct Costs

  • 84948.00
  • Sponsor Award Id

  • Contributor

  • Carolina Salvador M.D.   Investigator  
  • Catherine Parker M.D.   Principal Investigator  
  • Erica Stringer-Reasor M.D.   Investigator  
  • Lisle Nabell M.D.   Investigator